During Dr Shaw’s career at the University of Florida in the 1990s, antibodies made for research purposes were licensed to outside companies for sale. Some of these are still today sold by vendors such as Cell Signaling Technology. EnCor Biotechnology was therefore formed at the end of 1999 initially to market antibody reagents made in Dr. Shaw's research laboratory at lower prices.[1] In late 2001 EnCor rented lab space at the Sid Martin Biotechnology Incubator, a facility dedicated to commercialization of intellectual property generated in the University of Florida. Following this move the EnCor laboratory produced an increasing number of novel antibodies which were made, characterized, documented, manufactured and subjected to rigorous quality control. The company quickly therefore increased the number of reagents available for sale and soon become profitable and, in 2006, relocated to Gainesville, Florida.[2]
EnCor has always collaborated with basic scientists and clinicians to produce articles in peer-reviewed scientific publications focused on the examination of various plasma, serum and CSF biomarkers of nervous system damage and degeneration. One of these is the phosphorylated, axonal form of the major neurofilament protein heavy chain protein which has the HGNC name NEFH,[3][4][5][6] though is usually referred to as pNF-H in the scientific literature. Two further studies describe novel EnCor assays for UCHL1[7] and alpha-synuclein,[8] two major brain proteins implicated in the development of Parkinson's and other neurological diseases. In 2022 EnCor, in collaboration with researchers at the University of Florida described a novel class of antibodies to neurofilament light chain with the HGNC name NEFL, although the protein is usually referred to as NF-L. Surprisingly, one class of these antibodies bind epitopes hidden in healthy neurons and their processes but which are revealed on degeneration. Another class of antibody to neurofilament NF-L was shown to bind only neurofilaments in healthy neurons and their processes but failed to recognize degenerating and degenerated neurons and processes.[9] The antibodies degeneration specific antibodies have been dubbed "DegenoTag" reagents and should have wide utility for researchers on neurodegeneration. By 2022, the EnCor product line had increased to over 250 items, the antibodies mostly being used for research purposes, with a particular focus on immunocytochemistry and western blotting, though many are also utilized for immunocytochemistry, immunoprecipitation and ELISA. Some have become useful for diagnostic histopathology and for monitoring the levels of protein biomarkers, of research and potential clinical utility. EnCor supplies reagents to research labs and other reagent companies such as Abcam, BioLegend, Thermo Fisher Scientific, EMD Millipore, and Bio-Techne. EnCor is well known for the quality of its cell, tissue and western blotting images, many of which have been made available on Wikipedia Commons and widely used in books, articles, posters, for teaching, advertising and many other purposes, see [1].
Key EnCor Publications
Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle J, Scheff S, Pike B, Anderson DK, Howland DR (Nov 2005). "Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury". Biochem. Biophys. Res. Commun. 336 (4): 1268–1277. doi:10.1016/j.bbrc.2005.08.252. PMID16176808.
Shaw G, Madorsky I, Li Y, Wang Y, Rana S, Fuller DD (August 2022). "Uman Type NF-L Antibodies Are Effective Reagents for the Imaging of Neurodegeneration". bioRxiv10.1101/2022.08.27.504533.
^Gresle MM, Shaw G, Jarrott B, Alexandrou EN, Friedhuber A, Kilpatrick TJ, Butzkueven H (Dec 2008). "Validation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis". J. Neurosci. Res. 86 (16): 3548–3555. doi:10.1002/jnr.21803. PMID18709652. S2CID1453588.
^Tinsley RB, Kotschet K, Modesto D, Ng H, Wang Y, Nagley P, Shaw G, Horne MK (Sep 2010). "Sensitive and specific detection of α-synuclein in human plasma". J. Neurosci. Res. 88 (12): 2693–2700. doi:10.1002/jnr.22417. PMID20648655. S2CID22613058.